鼻塞通治疗持续性变应性鼻炎32例

目的 评价鼻塞通外用治疗持续性变应性鼻炎（AR）的临床疗效和安全性。方法64例持续性AR患者按1∶1的比例随机分为观察组和对照组,观察组经鼻外用鼻塞通溶液治疗2周（每侧鼻孔2次/d）,对照组口服氯雷他定片（10 mg/次,1次/d）,分别于治疗前及治疗1、2周后进行评估。比较治疗前后患者鼻眼症状总体评分、视觉模拟量表（VAS）、鼻结膜炎生存质量问卷评分（RQLQ）和鼻炎发作天数的变化,并评估鼻塞通的安全性。结果组内比较,两组患者治疗1周后和治疗2周后的鼻眼症状总体评分、VAS和RQLQ评分呈下降趋势,鼻炎发作天数减少,差异有统计学意义（P<0.01）。组间比较,两组患者治疗1周后的组间差异无统计学意义(P>0.05),但治疗2周后,观察组的鼻眼症状总体评分、VAS评分和鼻炎发作天数均低于对照组,差异有统计学意义（P<0.01）,两组的RQLQ比较,差异无统计学意义(P>0.05)。结论外用鼻塞通溶液可以有效减轻持续性AR患者的临床症状,提高生存质量,并减少AR急性发作的天数,疗效优于氯雷他定片,且安全性好。

Clinical study of Bisaitong in the treatment of 32 patients with persistent allergic rhinitis

Objective To evaluate the clinical efficacy and safety of Bisaitong for external use in the treatment of persistent allergic rhinitis (AR). Methods According to the random number table, 64 patients with persistent AR were randomly divided into treatment group and control group. The treatment group was treated with Bisaitong for 2 weeks, and the control group was given with loratadine tablets. Visiting was carried before treatment, 1 week after treatment and 2 weeks after treatment. Before and after treatment, we compared the overall score of nose and eye symptoms, visual analogue scale (VAS), quality of life questionnaire score of rhinoconjunctivitis (RQLQ) and rhinitis attack days. The safety of Bisaitong was also evaluated. Results Within the group comparison, the overall scores of the nose and eye symptoms, VAS and RQLQ scores of the two groups showed a significant downward trend after 1 week treatment and 2 weeks treatment; with the number of rhinitis attack days significantly decreased (P<0.01). Compared between the 2 groups, the difference between the two groups after 1 week of treatment was not statistically significant (P>0.05); but after 2 weeks of treatment, the overall score of nose and eye symptoms, VAS score and days of rhinitis attack were lower in the treatment group than the control group (P<0.01). There was no significant difference in RQLQ between the two groups (P>0.05). Conclusion Bisaitong can effectively reduce the clinical symptoms of patients with persistent AR, improve the quality of life, and reduce the days of rhinitis attack. The effect of Bisaitong is better than loratadine tablets, and it is safe.